SECTION 1. Notwithstanding any general or special law to the contrary, there shall be a special commission established to assess contracts between the MassHealth program and pharmaceutical benefit managers. The commission shall be tasked with, but not be limited to, evaluating the possible transition of MassHealth from its existing drug purchasing contract model with pharmaceutical benefit managers to a pass-through model.
The commission shall consist of 10 members: the state auditor, or a designee; the secretary of health and human services, or a designee; the director of MassHealth, or a designee; the director of insurance, or a designee; the speaker of the house of representatives, or a designee; the senate president, or a designee; the minority leader of the house of representatives, or a designee; the minority leader of the house, or a designee; one member who shall advocate on behalf of pharmaceutical benefit managers, to be appointed by the governor; and one member who shall advocate on behalf of pharmacies, to be appointed by the governor.
The commission shall submit its report and findings, along with any draft of legislation, to the house and senate committees on ways and means, the joint committee on health care financing, and the clerks of the house of representatives and the senate within 1 year of the passage of this act.
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.